Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib + Chemotherapy in Pediatric Relapsed/Refractory Acute Leukemia
NCT06376162Phase 1Recruiting
- Sponsor
- PedAL BCU
- Start
- Mar 2025
- Primary completion
- Mar 2033
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of ziftomenib in acute leukemia, sponsored by PedAL BCU. Primary endpoints: Dose-limiting Toxicity and Area Under the Plasma Concentration-time Curve at Cycle 2. Started Mar 2025; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT06376162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06376162.